Although I'm sure NVS will spend a small fortune trying to position Tasigna as a "cure", the reality is the drug is ineffective against the most common mutation. Who are you going to believe the pharma rep or key opinion leaders like Cortez, Druker, and Shaw?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.